Capital Research Global Investors’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$32.7M Hold
925,448
0.01% 385
2025
Q4
$37.6M Sell
925,448
-107,285
-10% -$4.67M 0.01% 367
2025
Q3
$48.6M Sell
1,032,733
-643,431
-38% -$33.4M 0.01% 348
2025
Q2
$87.3M Buy
1,676,164
+2,760
+0.2% +$151K 0.02% 299
2025
Q1
$101M Buy
1,673,404
+96,232
+6% +$6.2M 0.02% 286
2024
Q4
$108M Buy
1,577,172
+32,630
+2% +$2.27M 0.02% 293
2024
Q3
$111M Sell
1,544,542
-164,899
-10% -$11.6M 0.02% 271
2024
Q2
$118M Buy
1,709,441
+248,647
+17% +$18.1M 0.03% 261
2024
Q1
$117M Sell
1,460,794
-1,296,314
-47% -$116M 0.03% 279
2023
Q4
$302M Buy
2,757,108
+289,996
+12% +$30M 0.07% 188
2023
Q3
$249M Sell
2,467,112
-4,935
-0.2% -$567K 0.07% 205
2023
Q2
$336M Buy
2,472,047
+70,297
+3% +$8.58M 0.09% 179
2023
Q1
$249M Buy
2,401,750
+209,356
+10% +$20.2M 0.07% 196
2022
Q4
$194M Buy
2,192,394
+452,982
+26% +$37.6M 0.06% 218
2022
Q3
$139M Buy
1,739,412
+208,823
+14% +$19.7M 0.05% 236
2022
Q2
$147M Buy
1,530,589
+391,233
+34% +$47M 0.05% 246
2022
Q1
$169M Buy
1,139,356
+12,300
+1% +$1.72M 0.04% 256
2021
Q4
$160M Buy
1,127,056
+103,061
+10% +$14.6M 0.04% 270
2021
Q3
$134M Buy
1,023,995
+78,000
+8% +$10.2M 0.03% 286
2021
Q2
$130M Buy
945,995
+113,900
+14% +$15.6M 0.03% 280
2021
Q1
$109M Buy
832,095
+113,795
+16% +$13.7M 0.03% 300
2020
Q4
$80.5M Buy
718,300
+23,800
+3% +$2.25M 0.02% 315
2020
Q3
$54.6M Buy
694,500
+110,000
+19% +$8.97M 0.02% 320
2020
Q2
$42.1M Sell
584,500
-866,000
-60% -$60.2M 0.01% 331
2020
Q1
$83.1M Sell
1,450,500
-706,151
-33% -$65.1M 0.03% 248
2019
Q4
$241M Sell
2,156,651
-113,511
-5% -$12.1M 0.07% 201
2019
Q3
$218M Hold
2,270,162
0.07% 200
2019
Q2
$194M Buy
2,270,162
+369,000
+19% +$30.3M 0.06% 207
2019
Q1
$158M Buy
1,901,162
+379,500
+25% +$27.6M 0.05% 229
2018
Q4
$97.7M Sell
1,521,662
-197,338
-11% -$13.5M 0.03% 263
2018
Q3
$136M Buy
1,719,000
+115,394
+7% +$8.93M 0.04% 271
2018
Q2
$117M Buy
1,603,606
+276,006
+21% +$18.8M 0.03% 283
2018
Q1
$84.1M Buy
1,327,600
+332,586
+33% +$19.9M 0.02% 304
2017
Q4
$50.7M Buy
995,014
+114,014
+13% +$5.94M 0.01% 337
2017
Q3
$46.2M Hold
881,000
0.01% 340
2017
Q2
$44.9M Sell
881,000
-202,000
-19% -$9.99M 0.01% 346
2017
Q1
$48.1M Sell
1,083,000
-167,719
-13% -$7.21M 0.02% 344
2016
Q4
$55.2M Hold
1,250,719
0.02% 328
2016
Q3
$50.1M Hold
1,250,719
0.02% 324
2016
Q2
$59.7M Hold
1,250,719
0.02% 309
2016
Q1
$52.5M Sell
1,250,719
-91,970
-7% -$3.61M 0.02% 326
2015
Q4
$59.1M Hold
1,342,689
0.02% 319
2015
Q3
$64.1M Buy
1,342,689
+150,041
+13% +$8.24M 0.02% 325
2015
Q2
$69.5M Buy
1,192,648
+389,648
+49% +$21M 0.02% 326
2015
Q1
$40.5M Hold
803,000
0.01% 363
2014
Q4
$36.1M Hold
803,000
0.01% 365
2014
Q3
$29.6M Buy
803,000
+400,000
+99% +$15.9M 0.01% 374
2014
Q2
$17.8M Sell
403,000
-72,000
-15% -$3.27M 0.01% 389
2014
Q1
$20.6M Hold
475,000
0.01% 373
2013
Q4
$20.2M Hold
475,000
0.01% 381
2013
Q3
$16.1M Hold
475,000
0.01% 410
2013
Q2
$14.8M Buy
+475,000
New +$15.4M 0.01% 401

Other funds holding CNMD

Capital Research Global Investors's CNMD Position: Q1 2026 in Review

Capital Research Global Investors held its CONMED (CNMD) position steady in Q1 2026 at 925,448 shares worth $32.7M. The position accounts for 0.01% of the portfolio, ranked #385.

Capital Research Global Investors first reported a position in CNMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $336M in Q2 2023. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Capital Research Global Investors held 925,448 shares of CONMED worth $32.7M as of Q1 2026.
  • Capital Research Global Investors left its CONMED share count unchanged in Q1 2026.
  • CONMED made up 0.01% of Capital Research Global Investors's portfolio in Q1 2026, its #385 holding.
  • Capital Research Global Investors first reported a position in CONMED in Q2 2013 and has held it in 52 quarters since.
  • Capital Research Global Investors's CONMED position peaked at $336M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.